Literature DB >> 15276471

Fibroblast growth factor 2 isoforms and cardiac hypertrophy.

Elissavet Kardami1, Zhi-Sheng Jiang, Sarah K Jimenez, Cheryl J Hirst, Farah Sheikh, Peter Zahradka, Peter A Cattini.   

Abstract

Fibroblast growth factor 2 (FGF-2), a multifunctional polypeptide that affects cell growth and differentiation and becomes upregulated by stress, is expressed as AUG-initiated 18 kDa FGF-2 or CUG-initiated 21-34 kDa (hi-FGF-2) isoforms. Animal models have provided strong evidence that FGF-2 is essential for the manifestation of overload- and angiotensin-induced cardiac hypertrophy. Nevertheless, studies to-date have not discriminated between the activities of 18 kDa FGF-2 and hi-FGF-2. Our recent work has pointed to a potent pro-hypertrophic effect of added hi-FGF-2, and a pro-apoptotic effect of sustained intracrine hi-FGF-2 signaling. In the future, it will be important to differentiate between the activities of the different FGF-2 isoforms in the context of adaptive and maladaptive myocardial hypertrophy and heart failure. Based on all available evidence, we propose that while the 18-kDa FGF-2 is a component of an adaptive trophic response, a switch to hi-FGF-2 accumulation would exacerbate hypertrophy and contribute to cell death, thus driving the myocardium towards a maladaptive phenotype. Copryright 2004 European Society of Cardiology

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276471     DOI: 10.1016/j.cardiores.2004.04.024

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  25 in total

1.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

2.  Fibroblast growth factor-23 but not sKlotho levels are related to diastolic dysfunction in type 1 diabetic patients with early diabetic nephropathy.

Authors:  Burcu Dogan; Izzet Hakki Arikan; Derya Guler; Nursen Keles; Banu Isbilen; Ferruh Isman; Aytekin Oguz
Journal:  Int Urol Nephrol       Date:  2016-01-12       Impact factor: 2.370

3.  The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury.

Authors:  Siyun Liao; Janet R Bodmer; Mohamad Azhar; Gilbert Newman; J Douglas Coffin; Thomas Doetschman; Jo El J Schultz
Journal:  J Mol Cell Cardiol       Date:  2010-01-29       Impact factor: 5.000

4.  Knockout of nuclear high molecular weight FGF2 isoforms in mice modulates bone and phosphate homeostasis.

Authors:  Collin Homer-Bouthiette; Thomas Doetschman; Liping Xiao; Marja M Hurley
Journal:  J Biol Chem       Date:  2014-11-11       Impact factor: 5.157

5.  Delineating the molecular and histological events that govern right ventricular recovery using a novel mouse model of pulmonary artery de-banding.

Authors:  Mario Boehm; Xuefei Tian; Yuqiang Mao; Kenzo Ichimura; Melanie J Dufva; Khadem Ali; Svenja Dannewitz Prosseda; Yiwei Shi; Kazuya Kuramoto; Sushma Reddy; Vitaly O Kheyfets; Ross J Metzger; Edda Spiekerkoetter
Journal:  Cardiovasc Res       Date:  2020-08-01       Impact factor: 10.787

6.  High molecular weight fibroblast growth factor-2 as a promising prognostic biomarker to predict the occurrence of heart failure in atrial fibrillation patients.

Authors:  Ling-Yue Sun; Xiang Qu; Ling-Zhi Chen; Xing-Xing Chen; Gao-Shu Zheng; Zhi-Ting Wang; Wei-Jian Huang; Hao Zhou
Journal:  Heart Vessels       Date:  2017-07-08       Impact factor: 2.037

7.  Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus.

Authors:  Lakshmi Mitreyi Gorugantula; Terry Rees; Jacqueline Plemons; Huey-Shys Chen; Yi-Shing Lisa Cheng
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-08

Review 8.  High molecular weight FGF2: the biology of a nuclear growth factor.

Authors:  K Chlebova; V Bryja; P Dvorak; A Kozubik; W R Wilcox; P Krejci
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

9.  Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD.

Authors:  Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Alexander Grabner; Ansel Philip Amaral; Manfred Fobker; Jörg Stypmann; Hermann Pavenstädt; Myles Wolf; Christian Faul; Marcus Brand
Journal:  Nephrol Dial Transplant       Date:  2014-05-29       Impact factor: 5.992

Review 10.  Fibroblast growth factor-2 and cardioprotection.

Authors:  Elissavet Kardami; Karen Detillieux; Xin Ma; Zhisheng Jiang; Jon-Jon Santiago; Sarah K Jimenez; Peter A Cattini
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.